Exelixis (EXEL) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
February 12, 2019 4:06 PM EST- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 -
- Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018 -
- GAAP Diluted EPS of $1.15 for the Fourth Quarter of 2018, $2.21 for the Full Year 2018 -
- Non-GAAP Diluted EPS of $0.37 for the Fourth Quarter of 2018, $1.43 for the Full Year 2018 -
- Conference Call and Webcast Today at 5:00 P.M. Eastern Standard... More
